Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide

References

• LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741216452599
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
   PubMed Web of Science ®Google Scholar
• VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summaryAm J Respir Crit Care Med2017195555758228128970
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD010844
   PubMed Web of Science ®Google Scholar
• OharJADonohueJFMono and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPDSemin Respir Crit Care Med201031332133320496301
   PubMed Web of Science ®Google Scholar
• VinckenWAumannJChenHHenleyMMcBryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J Chron Obstruct Pulmon Dis2014921522824596459
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• CalverleyPMBurgePSSpencerSAndersonJAJonesPWBronchodilator reversibility testing in chronic obstructive pulmonary diseaseThorax200358865966412885978
   PubMed Web of Science ®Google Scholar
• CazzolaMDi MarcoFSantusPThe pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulm Pharmacol Ther2004171353914643169
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• JamesGDDonaldsonGCWedzichaJANazarethITrends in management and outcomes of COPD patients in primary care, 2000–2009: a retrospective cohort studyNPJ Prim Care Respir Med2014241401524990313
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax200863759259818245142
   PubMed Web of Science ®Google Scholar
• CazzolaMAndòFSantusPA pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPDPulm Pharmacol Ther200720555656116914336
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlisten Study GroupGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax201570651952725841237
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studiesRespir Med201510991155116326117292
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian RespiratoryClinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• SousaARRileyJHChurchAZhuCQPunekarYSFahyWAThe effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group studyNPJ Prim Care Respir Med2016261603127334739
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• WedzichaJASinghDVestboJExtrafine beclomethasone/formoterol in severe COPD patients with history of exacerbationsRespir Med201410881153116224953015
   PubMed Web of Science ®Google Scholar
• ShortPMWilliamsonPAElderDHJLipworthSIWSchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta2 agonist therapy in COPDChest20121411818621799028
   PubMed Web of Science ®Google Scholar
• LeeTAWilkeCJooMOutcomes associated with tiotropium use in patients with chronic obstructive pulmonary diseaseArch Intern Med2009169151403141019667304
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• Lopez-CamposJLAgustiAHeterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposalLancet Respir Med20153972973426165134
   PubMed Web of Science ®Google Scholar
• ChapmanKRBergeronCBhutaniMDo we know the minimal clinically important difference (MCID) for COPD exacerbations?COPD201310224324923514218
   PubMedGoogle Scholar
• WedzichaJACalverleyPMRabeKFRoflumilast: a review of its use in the treatment of COPDInt J Chron Obstruct Pulmon Dis201611819026792988
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• UsmaniOSTreating the small airwaysRespiration20128444145323154684
   PubMed Web of Science ®Google Scholar
• HanMKQuibreraPMCarrettaEEFrequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohortLancet Respir Med20175861962628668356
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• SinghDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesBr J Clin Pharmacol201579569570825377687
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• LiapikouAToumbisMTorresAManaging the safety of inhaled corticosteroids in COPD and the risk of pneumoniaExpert Opin Drug Saf20151481237124726113207
   PubMed Web of Science ®Google Scholar
• FabbriLMRoversiSBeghèBTriple therapy for symptomatic patients with COPDLancet2017389100821864186528385354
   PubMed Web of Science ®Google Scholar